ASSESSMENT OF INFLAMMATORY STATUS IN METABOLIC SYNDROME

Nivesh Krishna; Anitha Roy; Savitha G

doi:10.22159/ajpcr.2018.v11i7.25744

Authors

Nivesh Krishna Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.
Anitha Roy Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.
Savitha G Department of Biochemistry, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i7.25744

Keywords:

C-reactive protein, Metabolic syndrome, Disorder, Inflammatory

Abstract

Objective: The aim of the present study was to assess the level of inflammation in metabolic syndrome (MetS) individuals by estimating C-reactive protein (CRP) in the individuals.

Methods: A total of 60 subjects were selected from those attending the outpatient department of a private hospital and divided into two groups (n=30): Group 1 - healthy individuals and Group 2 - individuals with MetS. Informed consent was obtained from the subjects before sample collection. 5 ml of fasting venous blood was collected and centrifuged at 3000 rpm to separate serum, and then, it was analyzed for fasting blood sugar (FBS) by glucose oxidase-peroxidase method, serum triglycerides (TGL) by colorimetric enzymatic method, and serum CRP by Turbilatex method using ERBA CHEM 5 plus analyzer.

Results: Mean body mass index level in control and MetS group is 22.73Â±2.14 and 35.53Â±3.57, respectively. Mean FBS levels in the control group and MetS group are 85.6Â±11.59 and 115.67Â±24.52, respectively. Mean TGL levels in the normal control group and MetS group are 105.63Â±30.26 and 181.07Â±47.76, respectively. Mean CRP levels in the normal control and MetS group are 3.17Â±1.22 and 8.34Â±2.48, respectively.

Conclusion: CRP level positively correlated with MetS. Evaluation of CRP can be used as a surrogate marker to assess the inflammatory status of MetS individuals.

Downloads

Download data is not yet available.

Author Biography

Nivesh Krishna, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.

Pharmacology

References

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation 2009;120:1640-5.

Priyalakshmi S, Sankari M. A review on metabolic syndrome and periodontal disease. IOSR J Dent Med Sci (IOSR-JDMS) 2014;13:1-5.

Mounika S, Savitha G. Association of periodontal diseases and metabolic syndrome. Res J Pharm Tech 2015;8:994-6.

Miles JM, Jensen MD. Counterpoint: Visceral adiposity is not causally related to insulin resistance. Diabetes Care 2005;28:2326-8.

Onat A. Metabolic syndrome: Nature, therapeutic solutions and options. Expert Opin Pharmacother 2011;12:1887-900.

Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014;2014:943162.

Saulo JA. Ursolic acid in experimental models and human subjects: Potential as an anti-obesity/overweight treatment? Cancer 2015;2015:1- 10.

Festa A, Dâ€™Agostino R Jr., Howard G, MykkÃ¤nen L, Tracy RP, Haffner SM, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The insulin resistance atherosclerosis study (IRAS). Circulation 2000;102:42-7.

TrÃ¸seid M, Seljeflot I, Arnesen H. The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol 2010;9:11.

Pollex RL, Hegele RA. Genetic determinants of the metabolic syndrome. Nat Clin Pract Cardiovasc Med 2006;3:482-9.

Poulsen P, Vaag A, Kyvik K, Beck-Nielsen H. Genetic versus environmental aetiology of the metabolic syndrome among male and female twins. Diabetologia 2001;44:537-43.

Farooqui AA, Farooqui T, Panza F, Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci 2012;69:741- 62.

Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.

Xu JW, Morita I, Ikeda K, Miki T, Yamori Y. C-reactive protein suppresses insulin signaling in endothelial cells: Role of spleen tyrosine kinase. Mol Endocrinol 2007;21:564-73.

Dâ€™Alessandris C, Lauro R, Presta I, Sesti G. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on ser307 and ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia 2007;50:840-9.

Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805-12.

Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: Molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005;288:H2031-41.

Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.

Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.

Koenig W, Sund M, FrÃ¶hlich M, Fischer HG, LÃ¶wel H, DÃ¶ring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 1999;99:237-42.

Maseri A, Biasucci LM, Liuzzo G. Inflammation in ischaemic heart disease. BMJ 1996;312:1049-50.

Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group. Lancet 1997;349:462-6.

Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004;28:674-9.

Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.

Sumner AE. Ethnic differences in triglyceride levels and high-density lipoprotein lead to underdiagnosis of the metabolic syndrome in black children and adults. J Pediatr 2009;155:S7.e7-11.

Ramdas J, Jella V. Elevated C reactive protein levels in obese individuals with metabolic syndromes. Int J Adv Med 2016;3:162-5.

Banks RE, Forbes MA, Storr M, Higginson J, Thompson D, Raynes J, et al. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995;102:217-23.

Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-37.

El-Wakkad A, El-Morsi Hassan N, El-Zayat SR, Sibaii H, El-Raof SA, El-Masry A. Multiple markers of diabetes in relation to abdominal obesity in obese Egyptian adolescent girls. Int J Pharm Pharm Sci 2012;4:276-81.

Al-Biati HA, Sahib AS, Ismail SH. Effects of metformin and glibenclaimide combination in Iraqi obese patients with metabolic syndrome. Int J Pharm Pharm Sci 2014;6:501-3.